Access cutting-edge low-grade glioma treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.
Access low-grade glioma specialists in Baltimore at no cost
This study follows strict safety protocols and ethical guidelines
All study-related low-grade glioma treatment provided free
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories prior to enrollment into any of the arms. The study will consist of a screening period, a treatment period, a
Sponsor: Day One Biopharmaceuticals, Inc.
Check if you qualify for this low-grade glioma clinical trial in Baltimore, MD
If you're searching for low-grade glioma treatment options in Baltimore, MD, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced low-grade glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.